Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 12/20 | 0.51 |
| ▸ | IGF1R | P08069 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 2/20 | 0.44 |
| ▸ | JAK1 | P23458 | 3/20 | 0.44 |
| ▸ | JAK3 | P52333 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 2/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL340100 | 0.95 | BRD4 (0.50) | BRD4IGF1RSYKJAK1JAK3 | |
| SCHEMBL17060850 | 0.94 | BRD4 (0.48) | BRD4IGF1RSYKJAK1JAK3 | |
| SCHEMBL29611041 | 0.94 | BRD4 (0.48) | BRD4IGF1RSYKJAK1JAK3 | |
| SCHEMBL29609967 | 0.94 | BRD4 (0.49) | BRD4IGF1RSYKJAK1JAK3 | |
| SCHEMBL1742681 | 0.94 | BRD4 (0.49) | BRD4IGF1RSYKJAK1JAK3 | |
| SCHEMBL1742682 | 0.94 | BRD4 (0.49) | BRD4IGF1RSYKJAK1JAK3 | |
| SCHEMBL340444 | 0.87 | JAK3 (0.49) | BRD4IGF1RSYKJAK1JAK3 | |
| SCHEMBL17060888 | 0.86 | BRD4 (0.58) | BRD4IGF1RSYKJAK1JAK3 | |
| SCHEMBL17060887 | 0.86 | BRD4 (0.56) | BRD4IGF1RSYKJAK1JAK3 | |
| SCHEMBL15323495 | 0.86 | JAK3 (0.40) | BRD4IGF1RJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2389372-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS INC (US) | 2015-09-09 | — | — | EP | claimed |
| US-20100190770-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | US | claimed |
| WO-2010085684-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | WO | claimed |
| EP-4009974-A1 | COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME | Rigel Pharmaceuticals, Inc. (US) | 2022-06-15 | — | — | EP | disclosed |
| WO-2021026451-A1 | COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-02-11 | — | — | WO | disclosed |
| US-20200216431-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2020-07-09 | — | — | US | disclosed |
| US-10556891-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-20180265503-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2018-09-20 | — | — | US | disclosed |
| US-10005767-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170137411-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-9248132-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9084795-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20140221352-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20130310364-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-8563716-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-8507675-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| EP-2565193-A1 | Compositions and methods for inhibition of the JAK pathway | Rigel Pharmaceuticals, Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| US-8324200-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100190770-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| WO-2010085684-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180265503-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | BRD4 910/4885IGF1R 3492/4885SYK 119/4885 |
| US-20170137411-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | BRD4 910/4885IGF1R 3492/4885SYK 119/4885 |
| US-20200216431-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | BRD4 910/4885IGF1R 3492/4885SYK 119/4885 |
| US-20100190770-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | BRD4 910/4885IGF1R 3492/4885SYK 119/4885 |
| US-20130310364-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | BRD4 910/4885IGF1R 3492/4885SYK 119/4885 |
| US-20140221352-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | BRD4 910/4885IGF1R 3492/4885SYK 119/4885 |
| US-10556891-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | BRD4 910/4885IGF1R 3492/4885SYK 119/4885 |
| US-10005767-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | BRD4 910/4885IGF1R 3492/4885SYK 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.